Three-year visual outcome and injection frequency of intravitreal ranibizumab therapy for neovascular age-related macular degeneration.

BACKGROUND To assess the 3-year visual outcome and injection frequency for patients on ranibizumab for neovascular age-related macular degeneration (NV-AMD). METHODS Retrospective case-note review of 174 treatment-naïve eyes of 156 patients with NV-AMD with 3-year follow-up was done at specific time points closest to 12, 24 and 36 months. RESULTS The… CONTINUE READING